发明公开
- 专利标题： TREATMENT OF BILE ACID DISORDERS
-
申请号： EP16782352.5申请日： 2016-09-30
-
公开(公告)号： EP3355908A1公开(公告)日： 2018-08-08
- 发明人: XU, Jing , STANISLAUS, Shanaka , CHEN, Mei-Hsiu M. , HALE, Clarence H. , VENIANT-ELLISON, Murielle
- 申请人： Amgen Inc.
- 申请人地址： One Amgen Center Drive Thousand Oaks, California 91320-1799 US
- 专利权人： Amgen Inc.
- 当前专利权人： Amgen Inc.
- 当前专利权人地址： One Amgen Center Drive Thousand Oaks, California 91320-1799 US
- 代理机构： Grünecker Patent- und Rechtsanwälte PartG mbB
- 优先权： US201562236050P 20151001
- 国际公布： WO2017059371 20170406
- 主分类号： A61K38/18
- IPC分类号： A61K38/18 ; A61P1/16
摘要：
The invention relates method of treating a patient in need thereof with a long acting agonist to the FGF21 signaling pathway. In a particular embodiment, the invention relates to the use of molecules that stimulate the FGF21 signaling pathway, such as long acting FGF21 polypeptides or agonist antibodies, to treat disorders or diseases associated with excess bile acid. The invention further relates to pharmaceutical formulations and dosing of long acting agonists of the FGF21 signaling pathway suitable for treating bile acid related disorders.
信息查询
IPC分类:
